| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/25/2002 | WO2002056907A2 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | WO2002056906A2 Use of mycobacterium w for the treatment of human immunodeficiency virus (hiv) disease infection |
| 07/25/2002 | WO2002056905A2 Molecular antigen array |
| 07/25/2002 | WO2002056893A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | WO2002056831A2 Immunogenic proteoliposomes, and uses thereof |
| 07/25/2002 | WO2002056830A2 The use of immature dendritic cells to silence antigen specific cd8+t cell function |
| 07/25/2002 | WO2002056828A2 Helper virus-free herpes virus amplicon particles and uses thereof |
| 07/25/2002 | WO2002040511A9 Dna sequence and microcine from escherichia coli strain dsm 6601 |
| 07/25/2002 | WO2002020830A3 Test systems based on transmembrane receptors from helminths and the use thereof for identifying and characterizing compounds |
| 07/25/2002 | WO2002020615A3 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 07/25/2002 | WO2002020466B1 Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
| 07/25/2002 | WO2002020039A3 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites |
| 07/25/2002 | WO2002019968A9 Genetically engineered co-expression dna vaccines, construction methods and uses thereof |
| 07/25/2002 | WO2002013765A3 Malaria immunogen and vaccine |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002005849A3 Transportation of nucleic acid substances |
| 07/25/2002 | WO2002004496A3 Fimh adhesin proteins and methods of use |
| 07/25/2002 | WO2002002642B1 Composition for pharmaceutical and cosmetic products |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001092891A3 Regulating lipid levels via the zmax1 or hbm gene |
| 07/25/2002 | WO2001088126A3 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 07/25/2002 | WO2001082788A3 Compounds and methods for the treatment and prevention of bacterial infection |
| 07/25/2002 | WO2001042297A9 Clasp-3 transmembrane protein |
| 07/25/2002 | WO2001032204A3 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 07/25/2002 | WO2001030812A9 Activation of hcv-specific t cells |
| 07/25/2002 | WO2001009187A9 Human monoclonal antibodies to her2/neu |
| 07/25/2002 | WO2001004157A9 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 07/25/2002 | WO2001003730A9 Unmarked deletion mutants of mycobacteria and methods of using same |
| 07/25/2002 | WO2001000829A9 Human endogenous retrovirus in breast cancer |
| 07/25/2002 | WO2001000665A9 Inhibitors of memapsin 2 and use thereof |
| 07/25/2002 | US20020100069 Treating heart defects; obtain tissue, incubate with modulator of transcription, evaluate tissue for defect |
| 07/25/2002 | US20020099188 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 07/25/2002 | US20020099181 Anti-fibroblast growth factor-8 monoclonal antibody |
| 07/25/2002 | US20020099178 Growth-associated protease inhibitor heavy chain precursor |
| 07/25/2002 | US20020099174 Filtration of plasma mixtures using cellulose-based filter aids |
| 07/25/2002 | US20020099169 Modulation of preferential transcription factor; obtain sample containing transcription factor, incubate with modulator, monitor transcriptional activity |
| 07/25/2002 | US20020099014 Method for treatment of insulin resistance in obesity and diabetes |
| 07/25/2002 | US20020099012 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/25/2002 | US20020099005 Mucin is present in a natural or modified form; includes delivery of DNA, RNA, PNA, polynucleotides and proteins into cells, tissues or organisms; gene therapy; customized therapeutics; vaccination; drug delivery |
| 07/25/2002 | US20020098583 Composition for use in the treatment of cell cycle defects, autoimmune diseases, aging, cancer, leukemia and psoriasis |
| 07/25/2002 | US20020098581 Carcinoma associated antigen (SK1) monoclonal antibodies against SK1, methods of producing these antibodies and use therefor |
| 07/25/2002 | US20020098580 MDM interacting protein and methods of use thereof |
| 07/25/2002 | US20020098573 Generating preferential vector nucleotide sequences; obtain nucleotide sequences, incubate with preferential exogenous nucleotide sequences, ligate, recover nucleotide sequences |
| 07/25/2002 | US20020098550 Nucleotide sequences coding membrane protein for use in treatment and prevention of endotoxin shock, viral disease, immflammation and tumors |
| 07/25/2002 | US20020098544 Polypeptide for use in screening bactericides |
| 07/25/2002 | US20020098540 Novel polypeptides, and nucleic acids encoding the same |
| 07/25/2002 | US20020098469 Extracorporeal methods for enhancing antigen presentation and immune responsiveness |
| 07/25/2002 | US20020098277 Proteins are reduced with thiol redox proteins and further reacted with cystamine or oxidized glutathione to prevent reoxidation |
| 07/25/2002 | US20020098204 Veterinary vaccines |
| 07/25/2002 | US20020098203 Immnunologically active substance embedded in microparticles consisting of starch with amylopectin content greater than 85%; non-crosslinked |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098197 Hla binding peptides and their uses |
| 07/25/2002 | US20020098194 Immunizing adult with symptoms of autoimmune disease with immunizing preparation comprising an Autoimmune Target Antigen and a Th2 Response Inducing Adjuvant |
| 07/25/2002 | US20020098192 Polyalkylene oxide-modified single chain polypeptides |
| 07/25/2002 | US20020098190 Delaying development of HMFG- and CEA- associated tumor by administering first antibody comprising light and heavy chain variable region sequences in SEQ ID NO:2 and NO:4, and second antibody comprising sequences in SEQ ID NO:6 and NO:8 |
| 07/25/2002 | US20020098189 Have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and products of toxins |
| 07/25/2002 | US20020098184 Comprising T-cell dependant antigen, or part thereof, and associated adjuvant which is adapted to stimulate T-cell lymphocyte via cell surface receptor CD28 |
| 07/25/2002 | US20020098181 Inoculating female birds in egg laying age with targeted colony-forming immunogen, allowing time sufficient to permit production in bird of antibody, harvesting eggs, separating antibody-containing contents |
| 07/25/2002 | US20020098173 Amyloid modulators of an A beta aggregation core domain and a modifying group coupled to it |
| 07/25/2002 | US20020098170 Herpes simplex virus type 1 ( HSV-1)-derived vector for selectively inhibiting maligant cells and methods for its use to treat cancer and to express desired traits in maligant and non-miligant mammalian cells |
| 07/25/2002 | US20020098166 Genetically modified cells and their use in the prophylaxis or therapy of disorders |
| 07/25/2002 | DE10102337A1 Preparing ester containing polyunsaturated fatty acids, useful e.g. in animal or human nutrition, by transforming organism with desaturase gene from Phaeodactylum tricornatum |
| 07/25/2002 | DE10055545A1 Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen For expression in eukaryotes optimized HPV 16 L1 and HPV 16 L2 coding DNA sequences |
| 07/25/2002 | CA2472481A1 Use of mycobacterium w for the treatment of human immunodeficiency virus (hiv) disease infection |
| 07/25/2002 | CA2437082A1 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |
| 07/25/2002 | CA2435180A1 A virus causing respiratory tract illness in susceptible mammals |
| 07/25/2002 | CA2435081A1 Method for producing polyunsaturated fatty acids, novel biosynthesis genes and novel plant expression constructs |
| 07/25/2002 | CA2435054A1 Chlamydia heat shock protein |
| 07/25/2002 | CA2434490A1 Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
| 07/25/2002 | CA2434350A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | CA2433862A1 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | CA2433316A1 Molecular antigen array |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2431212A1 Immunogenic proteoliposomes, and uses thereof |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2430589A1 Helper virus-free herpes virus amplicon particles and uses thereof |
| 07/25/2002 | CA2427643A1 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc) |
| 07/24/2002 | EP1225225A2 Osteogenic devices |
| 07/24/2002 | EP1225224A1 Shear stress-response dna |
| 07/24/2002 | EP1225220A1 Dna encoding endo-beta-galactosidase |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1225180A2 Process for the production of virus-inactivated human gammaglobulin G |
| 07/24/2002 | EP1224942A1 Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| 07/24/2002 | EP1224471A2 Dpi-6, a therapeutic biomarker in neurological disorders |
| 07/24/2002 | EP1224461A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 07/24/2002 | EP1224311A1 Recombinant, replication defective celo virus and celo virus dna |
| 07/24/2002 | EP1224298A1 Fibrinolytically active polypeptide |
| 07/24/2002 | EP1224291A1 Multiple sclerosis-related superantigen |
| 07/24/2002 | EP1224286A2 Gene mining system and method |
| 07/24/2002 | EP1224282A2 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224274A1 Tumor necrosis factor related receptor, tr6 |
| 07/24/2002 | EP1224268A1 Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
| 07/24/2002 | EP1224264A2 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224215A1 NON-ANAPHYLACTIC FORMS OF GRASS POLLEN Ph1 p 6 ALLERGEN AND THEIR USE |
| 07/24/2002 | EP1224214A1 Redox reversible hcv proteins with native-like conformation |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |